Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.

Ciaran N Kohli-Lynch James Lewsey Kathleen Anne Boyd Dustin D FrenchNeil JordanAndrew E MoranNaveed Sattar David Preiss Andrew H Briggs

Published in: Circulation (2022)

Generic pricing has rendered preventive statin therapy cost-effective for many adults. ARR-guided therapy is more effective than 10-year risk scoring and is cost-effective.

Keyphrases

cardiovascular disease
type diabetes
coronary artery disease
stem cells
metabolic syndrome
mesenchymal stem cells
cell therapy
bone marrow